Activation and inhibition of the endogenous opioid system in human heart failure

K G Oldroyd, C E Gray, R Carter, K Harvey, W Borland, G Beastall, S M Cobbe

Abstract

Background—In a canine model of congestive heart failure β endorphin concentrations were high and opioid receptor antagonists exerted beneficial haemodynamic effects. In humans previous studies have suggested that opioid peptides may modify the perception of breathlessness and fatigue in heart failure.

Methods—Plasma concentrations of β endorphin were measured in patients with acute and chronic heart failure and cardiogenic shock. A subgroup of eight patients with New York Heart Association (NYHA) class III–IV heart failure was assessed for acute haemodynamic effects of naloxone, an opioid receptor antagonist. A separate group of 10 patients with class II–III heart failure, was randomised to a double blind placebo controlled study of the effects of intravenous naloxone on cardiopulmonary exercise performance.

Results—Plasma concentrations of β endorphin were usually normal in patients with chronic heart failure and did not correlate with severity as assessed by NYHA class. In 29% of patients with acute heart failure and 71% of those with cardiogenic shock β endorphin concentrations were high. The median concentration in the cardiogenic shock group was significantly higher than in either of the two heart failure groups and there was some evidence of a relation between β endorphin concentrations and survival. At the doses tested, naloxone was unable to modify systemic haemodynamics, exercise performance, or symptoms in patients with chronic congestive heart failure.

Conclusions—Circulating concentrations of β endorphin are usually normal in patients with chronic congestive heart failure. Inhibition of the endogenous opioid system is unlikely to have therapeutic potential in heart failure.

(Br Heart J 1995;73:41–48)

Keywords: heart failure, endogenous opioids.

Endogenous opioid systems are normally quiescent and most cells containing opioid peptides do not release them continuously. Their activation depends upon disruption of homeostasis after the real or perceived imposition of "stress". When opioids are released they generally exert an inhibitory effect on other physiological systems such as pain perception, respiratory and cardiovascular performance, gastrointestinal transit, and certain immunological and behavioural functions. Plasma concentrations of β endorphin, a potent endogenous opioid peptide, are acutely raised in most patients with myocardial infarction. They are also increased in a canine model of congestive heart failure, unrelated to any evidence of myocardial ischaemia, and in this model opioid receptor antagonists exert beneficial haemodynamic effects. In a pattern analogous to their involvement in pain sensation during myocardial ischaemia, opioid peptides may also modify the perception of breathlessness and fatigue in heart failure. Thus by a variety of mechanisms endogenous opioid peptides may contribute to the pathophysiology of heart failure.

We postulated that circulating concentrations of β endorphin would be raised in human heart failure and that an opioid antagonist would have beneficial effects on systemic haemodynamics, cardiopulmonary exercise performance, and symptoms.

Patients and methods

All of the study protocols received approval from the Ethics Committee of Glasgow Royal Infirmary.

NEUROENDOCRINE ASSAYS

The β endorphin radioimmunoassay has been independently validated in this institution and the method has been described previously. The antisera used are unusually specific, with only 1–6% cross reactivity with synthetic human lipotrophic pituitary hormone (β LPH, Peninsula Corporation). The normal range (mean ± 2 SDs) of this assay in 60 volunteers sampled at 0900 was 2.5–7.2 pmol/l. The SD of repeated measurements of β endorphin calculated according to the method of Bland and Altman was 0.5 pmol/l. Adrenocorticotropic hormone (ACTH) was measured by radioimmunoassay in unextracted plasma according to the method of Nicholson et al. Cortisol was measured in a direct solid phase radioimmunoassay system. Arginine vasopressin (AVP) and angiotensin II were measured with standard well described radioimmunoassays.

NALOXONE ASSAY

This was modified from a previously published method with the main improvement
being in the method of extraction. Naloxone and the internal standard naltrrexone were extracted from serum by solid phase techniques and measured by high performance liquid chromatography with electrochemical detection. The lower limit of detection was 10 nmol.l⁻¹ with a mean recovery of 95% from 1 ml samples of serum spiked with 500 pmol of naloxone. The following drugs were shown not to interfere: dihydrocodeine to 4-5 μmol.l⁻¹, codeine to μmol.l⁻¹, salicylate, to 1-5 mmol.l⁻¹, paracetamol to 1-0 mmol.l⁻¹, propranolol, metoprolol, diltiazem, nifedipine, and captopril. Precision was 5-0% at 200 nmol.l⁻¹ and 4-8% at 900 nmol.l⁻¹.

ASSessment of Left Ventricular Ejection Fraction

This was performed with cross sectional echocardiography and all scans were acquired and analysed by one experienced observer (KGO) with an ATL Ultramark 8 system. Simpson's formula was used to calculate left ventricular volumes. In our hands, the SD of repeated measurements of left ventricular ejection fraction by this technique is 3-35% with a normal result being >55%.β

β-Endorphin Concentrations in Patients with Heart Failure or Cardiogenic Shock

Opioid peptide concentrations were measured on a single occasion in three groups of patients with heart failure or cardiogenic shock. Patients with stable congestive heart failure were recruited from out patient clinics. Patients with acute or acute to chronic congestive heart failure or cardiogenic shock were identified from emergency admissions to the coronary or intensive care units. Other than this, patients were unselected and recruited consecutively.

Heart failure was defined on clinical criteria and evidence of ventricular dysfunction on echocardiography or radionuclide ventriculography. Cardiogenic shock was defined by the criteria of Cohn. Patients with heart failure or cardiogenic shock but recent myocardial infarction (<48 hours) or ongoing chest pain were excluded. We have previously shown that in patients with acute myocardial infarction, the high β endorphin concentrations seen on admission have in all cases returned to normal within this period.

Acute Haemodynamic Effects of Naloxone in Congestive Heart Failure

Patients

Patients with stable chronic congestive heart failure were eligible for this study. All cardioactive drug treatment, other than sublingual glyceryl trinitrate, was withdrawn for at least 36 hours. Patients were admitted to hospital one day before the planned study and a Swan-Ganz triple lumen thermodilution catheter was placed in the pulmonary artery percutaneously through the femoral or internal jugular vein. Patients were confined to bed overnight and for the duration of the study the next morning. Only a light breakfast of tea and toast was allowed.

Haemodynamic Measurements

Heart rate was recorded continuously and blood pressure was measured non-invasively by a semiautomatic electronic cuff sphygmonomanometer (Hewlett Packard). Right atrial, pulmonary artery, and pulmonary capillary wedge pressures were recorded with electronically calibrated transducers and a seven channel ink jet chart recorder (Siemens Mingograf 7). The pressure recordings were all digitised on line to provide mean and phasic values that were immediately entered into a microcomputer (Epson HX-20) linked to an American Edwards cardiac output computer.

Protocol

Naloxone administration schedules were designed from previously published pharmacokinetic data and aimed to achieve plasma concentrations in the range 1-100 nmol.l⁻¹. At these concentrations in vitro, antagonism at all opioid receptor subtypes can be expected. Naloxone was given intravenously by incremental infusion starting at 1-0 μg.kg⁻¹ min⁻¹ with an approximate doubling of the dose every 20-30 minutes up to 20-0 μg.kg⁻¹ min⁻¹. Bolus doses were given before each increase in the infusion to accelerate a steady state in plasma concentrations. Haemodynamic data were acquired twice 30 minutes apart at baseline and the results were averaged. Thereafter measurements were made immediately before each increase in dose and 45-60 minutes after the end of the naloxone infusion. Plasma samples were taken at baseline, before each increase in naloxone and 45-60 minutes after the end of the infusion for the measurement of β endorphin, ACTH, cortisol, and naloxone.

Acute Effects of Naloxone on Exercise Performance and Symptoms in Patients with Congestive Heart Failure

Patients

Patients for this study were selected from outpatient clinics. Inclusion criteria were impaired left ventricular function secondary to ischaemic heart disease or dilated cardiomyopathy and a reduced exercise tolerance limited by dyspnoea or fatigue but not angina or exercise induced myocardial ischaemia. Patients who had valvar heart disease, evidence of significant pulmonary disease, or resting pulmonary function tests (FEV₁/FVC <40%), or who could not consistently reproduce their maximal oxygen consumption during the practice exercise tests were excluded. All patients gave fully informed written consent before entry into the study.

Exercise Tests

Maximal symptom limited cardiopulmonary treadmill exercise tests with 12 lead electrocardiographic monitoring were performed with the standardised exponential exercise protocol (STEEP). This protocol produces exponential rather than linear increases in workload in one minute increments. The small frequent increases minimise problems of patient boredom and the learning effect, while
facilitating the detection of an anaerobic threshold. Respiratory gas exchange was measured with a closed loop breathing circuit. The inspired limb of the circuit was fitted with a turbine ventilometer and the expired limb connected to a mixing chamber from which expiratory gases were measured with polarographic oxygen and infrared carbon dioxide analysers. The output of the ventilometer and gas analysers were processed by an on line microcomputer to allow continuous measurement of respiratory gas exchange and inspired minute ventilation (PK Morgan Exercise Test System).

Symptoms
Visual analogue scales for dyspnoea and fatigue were displayed on the monitor of a BBC microcomputer as horizontal uncalibrated bars, annotated with the words "none" at one end and "severe" at the other. With a linear potentiometer mounted on the treadmill and inputting directly to the microcomputer, patients were able to indicate their estimation of the severity of the relevant symptom during exercise by moving the position of a cursor from extreme left (equivalent to a score of 0) to extreme right (a score of 100). The modified Borg score was also used at peak exercise. As a measure of dyspnoea, both visual analogue scales and the Borg score correlate well with measured ventilation, the relation being predominantly linear.\(^1\)

Protocol
At least two practice tests and all of the exercise tests were performed between 0900 and 1200. Immediately before each of the three study exercise tests and after the patients were breathing through the closed respiratory loop of the gas analysing system, each patient received a double blind randomised order, either placebo or naloxone (0.1 mg.kg\(^{-1}\) or 1-0 mg.kg\(^{-1}\)) given as a slow bolus intravenous injection over one minute. End points in this study were breathlessness and fatigue assessed as already described and the following measures of cardiovascular and respiratory performance: exercise time, maximal \(O_2\) consumption (\(V_{O_2}\)max) and \(CO_2\) production (\(V_{CO_2}\)), transcutaneous \(O_2\) and \(CO_2\) saturation, \(O_2\) consumption at the anaerobic threshold, ventilation (VE), respiratory dead space, and tidal volume. Symptoms were assessed twice during exercise; firstly when the patient had reached 60% of his previously found \(V_{O_2}\)max and secondly at peak exercise. Peripheral venous blood samples were drawn from an indwelling cannula before and after exercise and assayed for naloxone, \(\beta\) endorphin, ACTH, and cortisol.

**DATA ANALYSIS**
In the observational study, \(\beta\) endorphin, ACTH, and cortisol results were skewed and so are reported as median (interquartile range) with groups being compared by Mann-Whitney U tests. Rank correlation coefficients were calculated by Spearman's method. Open label naloxone was given in the haemodynamic studies but the data were digitised and analysed on line by microcomputer. This removed, to some extent, the problems of within-observer variability and bias. Accordingly, further analysis by an independent observer was not performed. Haemodynamic and exercise variables were normally distributed and are reported as mean(SD) or mean(SEM). Group comparisons were made by repeated measures or one way analysis of variance followed by modified t tests if appropriate.

**Results**
\(\beta\) ENDORPHIN CONCENTRATIONS IN PATIENTS WITH HEART FAILURE OR CARDIogenic SHOCK
The number of patients with concentrations >the upper limit of normal was three of 34 (9%) with chronic heart failure, eight of 28 (29%) with acute heart failure, and 10 of 14 (71%) with cardiogenic shock (fig 1 and table 1). Median values in the heart failure groups were not significantly different from each other. Two of the three patients with chronic heart failure and high concentrations were in NYHA class III (\(\beta\) endorphin 8-2 and 10-2 pmol.l\(^{-1}\)) and the other was in class IV (\(\beta\) endorphin 13-3 pmol.l\(^{-1}\)). Patients with cardiogenic shock had significantly higher concentrations than either of the two heart failure groups. The four patients with cardiogenic

| Table 1 Circulating concentrations (median (interquartile range)) of \(\beta\) endorphin, ACTH, and cortisol in patients with congestive heart failure (CHF) and cardiogenic shock |
|-----------------|----------------|----------------|
| \(\beta\) endorphin (pmol.1\(^{-1}\)) | No ACTH (nmol.1\(^{-1}\)) | No Cortisol (nmol.1\(^{-1}\)) |
| Chronic CHF | 34 | 4-4 (3-7-4) | 34 | 1.0 (1-0-3-3) | 31 | 323* (255-500) |
| Acute CHF | 28 | 5-2** (3-8-7-8) | 28 | 1.0 (1-0-3-6) | 27 | 690** (500-898) |
| Cardiogenic shock | 14 | 9-8** (6-8-25-0) | 14 | 3-9** (1-0-19-0) | 12 | 1302** (1127-2540) |

*P < 0-001 v acute CHF, ** P < 0-01 v chronic CHF.

---

**Figure 1 Individual \(\beta\) endorphin concentrations in consecutive patients with chronic (CCHF) or acute (ACHF) congestive heart failure or cardiogenic shock (CS).**
Table 2
Clinical details of the patients with chronic congestive heart failure studied to assess the acute effects of naloxone on haemodynamic, symptoms and exercise capacity

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>NYHA</th>
<th>Diagnosis</th>
<th>LVEF (%)</th>
<th>Frusemide (mg.day⁻¹)</th>
<th>FEV/FVC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>F</td>
<td>III-IV</td>
<td>DCM</td>
<td>18</td>
<td>160</td>
<td>—</td>
</tr>
<tr>
<td>50</td>
<td>M</td>
<td>III</td>
<td>BHD</td>
<td>15</td>
<td>160</td>
<td>—</td>
</tr>
<tr>
<td>56</td>
<td>M</td>
<td>IV</td>
<td>BHD</td>
<td>15</td>
<td>80</td>
<td>—</td>
</tr>
<tr>
<td>65</td>
<td>M</td>
<td>IV</td>
<td>BHD</td>
<td>17</td>
<td>80</td>
<td>—</td>
</tr>
<tr>
<td>48</td>
<td>M</td>
<td>IV</td>
<td>BHD</td>
<td>20</td>
<td>250</td>
<td>—</td>
</tr>
<tr>
<td>60</td>
<td>M</td>
<td>III</td>
<td>BHD</td>
<td>21</td>
<td>120</td>
<td>—</td>
</tr>
<tr>
<td>56</td>
<td>M</td>
<td>III-IV</td>
<td>DCM</td>
<td>25</td>
<td>240</td>
<td>—</td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>III-IV</td>
<td>DCM</td>
<td>19</td>
<td>80</td>
<td>—</td>
</tr>
</tbody>
</table>

Haemodynamic study (n = 8)

Exercise study (n = 10)

LVEF, left ventricular ejection fraction; FEV/FVC, forced expiratory volume in 1 forced vital capacity; IHD, ischaemic heart disease; DCM, dilated cardiomyopathy.

shock and normal β endorphin concentrations all survived their initial stay in hospital, as did one other patient with cardiac shock whose β endorphin concentration on admission was marginally high at 7-8 pmol.l⁻¹. β Endorphin concentrations were high in eight of the nine patients with cardiogenic shock who did not survive to discharge. The median (interquartile range) concentration in the survivors was 6-8 (4-9-7-2) pmol.l⁻¹ vs 18-7 (11-5-34-1) pmol.l⁻¹ in the non-survivors, P = 0-01. Of all 76 patients, β endorphin concentrations were significantly lower in the 63 patients who survived their stay in hospital than the 13 who did not (4-9 (3-7-6-7) pmol.l⁻¹ vs 13-6 (6-4-25-0) pmol.l⁻¹ P = 0-001).

Relation between β endorphin concentrations and other neuroendocrine and clinical variables

Table 1 shows that median ACTH concentrations were similar in the two heart failure groups but patients with cardiogenic shock had a significantly higher ACTH concentration than those with chronic heart failure. There was a significant positive correlation between β endorphin concentrations and ACTH (r = 0-58, P = 0-0001, n = 76).

Median cortisol concentrations in each of the three groups were significantly different from each other. There was a weak positive correlation between cortisol and β endorphin concentrations (r = 0-36, P = 0-003, n = 70).

Within all patients, univariate rank correlation analysis showed no significant relation between β endorphin concentrations and any of the following: age, aetiology of heart failure, heart rate, systolic and diastolic blood pressure, jugular venous pressure, simultaneously measured concentrations of creatinine or angiotensin II, left ventricular ejection fraction, and the daily dose of frusemide. There was a weak but significant correlation between β endorphin and arginine vasopressin (r = 0-46, P = 0-005, n = 38). β endorphin concentrations were not different in patients with and without cardiomegaly or pulmonary oedema.

Considering only the patients with chronic heart failure, there were no significant correlations between β endorphin concentration and either New York Heart Association (NYHA) class or the use of angiotensin converting enzyme (ACE) inhibitors. In six patients β endorphin was measured before and one week after the start of treatment with captopril. The plasma concentration increased in five of six patients and was unchanged in the sixth; median (interquartile range) concentration before treatment was 4-0 (3-6-5-0) pmol.l⁻¹ vs 4-4 (3-7-5-8) pmol.l⁻¹ one week later, P = 0-10.

ACUTE HAEMODYNAMIC EFFECTS OF NALOXONE IN PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE

Table 2 shows the clinical characteristics of the eight patients included in this study. Their mean age was 52 (range 24-70) and all were in NYHA class III-IV. In six of eight patients the aetiology of their heart failure was ischaemic heart disease, the other two patients had dilated cardiomyopathy. The mean left ventricular ejection fraction was 19% (range 15-25%) and the mean daily dose of frusemide was 145 (range 80-250) mg.day⁻¹. No adverse effects were reported during the naloxone infusion by any of the patients. Naloxone had no significant effects on any of the variables measured (table 3).

Table 3

<table>
<thead>
<tr>
<th>Naloxone (µg.kg⁻¹.min⁻¹)</th>
<th>Control</th>
<th>1-0</th>
<th>2-5</th>
<th>5-10</th>
<th>20-50</th>
<th>After</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beat.min⁻¹)</td>
<td>94 (7)</td>
<td>92 (7)</td>
<td>92 (7)</td>
<td>91 (6)</td>
<td>86 (9)</td>
<td>87 (11)</td>
<td>96 (9)</td>
</tr>
<tr>
<td>Arterial pressure (mm Hg)</td>
<td>94 (4)</td>
<td>93 (4)</td>
<td>93 (3)</td>
<td>97 (5)</td>
<td>80 (9)</td>
<td>92 (4)</td>
<td>101 (6)</td>
</tr>
<tr>
<td>Right atrial pressure (mm Hg)</td>
<td>4 (1)</td>
<td>5 (2)</td>
<td>6 (2)</td>
<td>6 (2)</td>
<td>7 (2)</td>
<td>3 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>PA pressure (mm Hg)</td>
<td>31 (5)</td>
<td>29 (4)</td>
<td>30 (3)</td>
<td>29 (3)</td>
<td>33 (4)</td>
<td>32 (6)</td>
<td>31 (4)</td>
</tr>
<tr>
<td>PAWP (mm Hg)</td>
<td>22 (3)</td>
<td>22 (3)</td>
<td>23 (2)</td>
<td>23 (2)</td>
<td>24 (3)</td>
<td>20 (3)</td>
<td>22 (4)</td>
</tr>
<tr>
<td>Cardiac output (l.min⁻¹)</td>
<td>5-2 (0-4)</td>
<td>4-9 (0-5)</td>
<td>4-5 (0-5)</td>
<td>4-8 (0-5)</td>
<td>4-8 (0-6)</td>
<td>5-1 (0-7)</td>
<td>4-9 (0-6)</td>
</tr>
<tr>
<td>SVI (ml.m⁻¹)</td>
<td>31 (4)</td>
<td>30 (4)</td>
<td>30 (4)</td>
<td>29 (3)</td>
<td>29 (4)</td>
<td>31 (4)</td>
<td>29 (4)</td>
</tr>
<tr>
<td>LVSWI (g.m⁻¹ min⁻¹)</td>
<td>29 (4)</td>
<td>28 (4)</td>
<td>28 (4)</td>
<td>29 (4)</td>
<td>29 (4)</td>
<td>31 (6)</td>
<td>28 (3)</td>
</tr>
<tr>
<td>RVSWI (g.m⁻¹ min⁻¹)</td>
<td>13 (2)</td>
<td>12 (2)</td>
<td>12 (2)</td>
<td>12 (2)</td>
<td>13 (1)</td>
<td>13 (2)</td>
<td>12 (3)</td>
</tr>
<tr>
<td>SVR (dyn s⁻¹cm⁻⁵)</td>
<td>1396 (164)</td>
<td>1472 (168)</td>
<td>1479 (176)</td>
<td>1568 (175)</td>
<td>1448 (133)</td>
<td>1491 (204)</td>
<td>1624 (262)</td>
</tr>
<tr>
<td>PVRI (dyn s⁻¹cm⁻⁵)</td>
<td>133 (19)</td>
<td>121 (28)</td>
<td>129 (34)</td>
<td>117 (23)</td>
<td>165 (54)</td>
<td>165 (54)</td>
<td>165 (54)</td>
</tr>
</tbody>
</table>

PA, pulmonary artery; PAWP, pulmonary artery wedge pressure; SVI, stroke volume index; LVSWI, left ventricular stroke work index; RVSWI, right ventricular stroke work index; SVR, systemic vascular resistance; PVRI, pulmonary vascular resistance.

Values are mean (SD).
Table 4  Effect of an incremental intravenous infusion of naloxone on the median interquartile range concentrations of β endorphin, ACTH, and cortisol in eight patients with congestive heart failure

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>After-naloxone</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>β Endorphin (pmol.l⁻¹)</td>
<td>4-2 (3-8-5-3)</td>
<td>5-8 (3-4-8-4)</td>
<td>0-44</td>
</tr>
<tr>
<td>ACTH (pg.ml⁻¹)</td>
<td>1-0 (1-0-1-0)</td>
<td>1-0 (1-0-3-4)</td>
<td>0-37</td>
</tr>
<tr>
<td>Cortisol (nmol.l⁻¹)</td>
<td>328 (270-486)</td>
<td>404 (336-650)</td>
<td>0-10</td>
</tr>
</tbody>
</table>

Plasma naloxone concentrations
The intravenous protocol used in these patients produced concentrations of >1 µmol.l⁻¹ in seven of eight patients with the eighth patient only reaching a peak concentration of 0-2 µmol.l⁻¹. The mean(SD) peak concentration in all eight patients was 11-0 (14-5) µmol.l⁻¹.

Neuroendocrine measurements
At baseline, one patient had a slightly raised β endorphin concentration (8-2 µmol.l⁻¹) but all of the other seven patients had normal concentrations. In two of these seven patients concentrations increased to above the upper limit of normal after intravenous naloxone. Overall, concentrations of β endorphin, ACTH, and cortisol tended to be higher after naloxone, but none of the differences from baseline reached significance (table 4).

Correlations between β endorphin concentrations and haemodynamic indices
Invasive haemodynamic data were available for a total of 22 patients including 14 from the observational study. Spearman rank correlation coefficients did not suggest any significant relations between β endorphin concentrations and heart rate, arterial pressure (phasic or mean), right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac index, stroke volume index, left or right ventricular stroke work index, and systemic or pulmonary vascular resistance.

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Naloxone (0-1 mg.kg⁻¹)</th>
<th>Naloxone (1-0 mg.kg⁻¹)</th>
<th>ANOVA</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double product (× 100)</td>
<td>180 (40)</td>
<td>182 (40)</td>
<td>173 (43)</td>
<td>0-24</td>
</tr>
<tr>
<td>Exercise time (s)</td>
<td>538 (147)</td>
<td>555 (197)</td>
<td>533 (169)</td>
<td>0-78</td>
</tr>
<tr>
<td>Time to 60% VO₂max (s)</td>
<td>274 (90)</td>
<td>309 (134)</td>
<td>283 (111)</td>
<td>0-63</td>
</tr>
<tr>
<td>VO₂max (ml.min⁻¹.kg⁻¹)</td>
<td>17-7 (3-8)</td>
<td>17-6 (4-6)</td>
<td>17-0 (3-4)</td>
<td>0-66</td>
</tr>
<tr>
<td>VO₂ at AT (ml.min⁻¹.kg⁻¹)</td>
<td>12-1 (1-7)</td>
<td>11-6 (1-6)</td>
<td>12-0 (1-6)</td>
<td>0-46</td>
</tr>
<tr>
<td>% predicted VO₂max</td>
<td>56-9 (9-6)</td>
<td>57-4 (13-6)</td>
<td>55-0 (11-0)</td>
<td>0-67</td>
</tr>
<tr>
<td>V̇Emax (l.min⁻¹)</td>
<td>56-6 (15-3)</td>
<td>56-1 (15-8)</td>
<td>57-3 (15-2)</td>
<td>0-80</td>
</tr>
<tr>
<td>V̇E/V̇CO₂</td>
<td>40-1 (12-8)</td>
<td>39-5 (12-0)</td>
<td>40-1 (10-0)</td>
<td>0-74</td>
</tr>
<tr>
<td>V̇A/ṠḊẏṗṅȯṡȧė at VO₂max</td>
<td>64 (12)</td>
<td>71 (10)</td>
<td>65 (10)</td>
<td>0-25</td>
</tr>
<tr>
<td>V̇A/ṠḊẏṗṅȯṡȧė at VO₂max</td>
<td>61 (13)</td>
<td>62 (12)</td>
<td>67 (9)</td>
<td>0-19</td>
</tr>
<tr>
<td>Borg score</td>
<td>4-3 (3-3)</td>
<td>4-7 (1-3)</td>
<td>4-1 (1-2)</td>
<td>0-33</td>
</tr>
<tr>
<td>Dyspnoea/V̇Emax</td>
<td>1-25 (0-57)</td>
<td>1-35 (0-34)</td>
<td>1-21 (0-42)</td>
<td>0-62</td>
</tr>
<tr>
<td>Plasma naloxone (µmol.l⁻¹)</td>
<td>0-31 (0-48)</td>
<td>0-31 (0-48)</td>
<td>0-0009</td>
<td></td>
</tr>
</tbody>
</table>

Table 5  Effects of the double blind administration of placebo and low and high doses of naloxone on cardiopulmonary function during symptoms limited treadmill exercise in 10 patients with stable congestive heart failure

Cardiopulmonary exercise variables
All 10 patients successfully completed each of their three study exercise tests. Table 5 shows the results. Neither dose of naloxone had any significant effect on the basal values of O₂ consumption or ventilation. Total exercise duration and the time to reach 60% of previously achieved VO₂max were similar in all three groups. Thus a similar workload was performed at each exercise test. The VO₂max and the VO₂ at the anaerobic threshold were virtually identical providing no evidence of either an increased exercise capacity or an improved exercise efficiency with naloxone (figure 2). Maximal ventilation was similar in...
all three groups, as was the ventilatory response to CO₂ production (VE/VCO₂).

**Symptoms**

Dyspnoea at both submaximal and maximal workloads was similar in all three groups. The ratio of the visual analogue score to ventilation at maximal workload was also not different between the groups. Visual analogue scores for fatigue were almost as high as those for dyspnoea and were not influenced by naloxone either at submaximal or maximal workloads.

**Neuroendocrine variables**

Before exercise, concentrations of β endorphin were similar at each of the three exercise tests ($F = 0.02$, $P > 0.8$). Within each group, concentrations after exercise were significantly higher after naloxone but not after placebo. Naloxone enhanced the exercise-induced increase in β endorphin concentrations in a dose dependent manner ($F = 4.35$, $P = 0.03$). Measurements of ACTH and cortisol were only available for eight patients. In 20 of 48 samples assayed, ACTH concentrations were below the lower limit of detection of the assay (2 pmol. l⁻¹). In these patients an arbitrary value of 1 pmol. l⁻¹ was inserted and the subsequent statistical comparisons were made with non-parametric techniques. The ACTH and cortisol concentrations were increased by exercise but none of the within group differences reached significance.

**Plasma naloxone concentrations**

After the lower dose of naloxone, mean plasma concentrations ranged from 0.05–1.56 μmol. l⁻¹ after exercise. The 10-fold higher dose increased plasma concentrations by an average of 26-fold with all patients exceeding 1 pmol. l⁻¹ and two exercised at 2 pmol. l⁻¹; range 1.04–22.10 pmol. l⁻¹. There were weak correlations between the plasma concentration of naloxone at the end of exercise and both the β endorphin concentration after exercise ($r = 0.48$, $P = 0.04$) and the percentage change in β endorphin concentrations induced by exercise ($r = 0.43$, $P = 0.07$).

**Correlations between β endorphin concentrations and exercise performance**

Simple linear regression analysis showed no significant correlations between β endorphin concentrations before or after exercise and any variable of cardiopulmonary exercise performance. This finding was consistent whether each of the three treatment groups were examined separately or together. There was also no correlation with visual analogue scores for fatigue, but in the placebo group, scores for dyspnoea correlation with concentrations after exercise ($r = -0.70$, $P = 0.04$). This relation was lost when the patients exercised after being given either a low dose ($r = 0.44$, $P = 0.23$) or high dose ($r = 0.43$, $P = 0.25$) of naloxone.

**Discussion**

**β ENDORPHIN CONCENTRATIONS IN PATIENTS WITH HEART FAILURE**

Kawashima et al reported a good correlation between NYHA class and β endorphin concentration in 37 patients with chronic congestive heart failure. In a similar group of patients with heart failure we found high β endorphin concentrations in only three patients and could not show any relationship with NYHA class. A larger proportion of our patients with acute heart failure and most of those with cardiogenic shock had high β endorphin concentrations. The significant differences between β endorphin concentrations in those patients surviving their stay in hospital both in the whole group and particularly in those with cardiogenic shock are intriguing. There may be some relation between the magnitude of a haemodynamic disturbance and the stimulus to opioid peptide release.

**OPIOID PEPTIDES AND ACE INHIBITORS**

The exercise induced euphoria reported by endurance athletes has been attributed to enhanced release of endogenous opioid peptides. This has also been offered as an explanation for the uplifting effect of most ACE inhibitors. In normal subjects, captopril did not increase concentrations of leu-enkephalin and met-enkephalin either before or after exercise, but it did enhance the exercise induced rise in the plasma concentration of β endorphin. In our patients with chronic heart failure, β endorphin concentrations were not higher in those taking an ACE inhibitor. In the six patients in whom concentrations were measured before and one week after the start of ACE inhibitor treatment, there was a trend towards higher concentrations.

---

Table 6 Effect of placebo and naloxone at low (0.1 mg·kg⁻¹) and high (1.0 mg·kg⁻¹) dose on plasma concentrations of β endorphin (n = 9), adrenocorticotrophin (n = 8, ACTH), and cortisol (n = 8) before and after exercise in patients with stable chronic congestive heart failure

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Naloxone (0.1 mg·kg⁻¹)</th>
<th>Naloxone (1.0 mg·kg⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
</tr>
<tr>
<td>β Endorphin</td>
<td>6.3 (2.7)</td>
<td>6.2 (2.8)</td>
</tr>
<tr>
<td>ACTH (pmol. l⁻¹)</td>
<td>1 (1.9)</td>
<td>1.5 (1.7-4)</td>
</tr>
<tr>
<td>Cortisol (nmol. l⁻¹)</td>
<td>380 (151)</td>
<td>353 (134)</td>
</tr>
</tbody>
</table>

*P < 0.05 v before exercise; **P < 0.05 v placebo. Values are mean (SD) except for ACTH, which are median interquartile range.
Activation and inhibition of the endogenous opioid system in human heart failure

HAEMODYNAMIC EFFECTS OF NALOXONE IN HEART FAILURE

In the canine model of chronic congestive heart failure studied by Liang et al, the intravenous dosage the opioid antagonist nal-mafene resulted in significant increases in mean arterial pressure, cardiac output, left ventricular dp/dt, and regional blood flow to the myocardium, skeletal muscle (quadri-ceps), and kidney. β Adrenoceptor blockade abolished the effects on cardiac output and ventricular contractility whereas α adrenocep-tor blockade prevented the pressor response. This clearly suggests that the beneficial effects were mediated through the sympathetic nervous system. Further studies indicated that the effects were produced centrally and were not related to any change in pain sensation.4,5

The failure of our study and a similar previous study27 to reproduce these haemodynamic effects in patients with severe congestive heart failure may be due to several differences between clinical heart failure in humans and that in the particular animal model used by Liang et al.4 Berger et al first described the use of tricupid valve avulsion and progressive pulmonary artery occlusion to produce stable heart failure in dogs.28 Although predominantly right sided failure develops, many of the haemodynamic, neuroendocrine, and biochemical features of clinical congestive cardiac failure including evidence of left ventricular dysfunction are also seen.29 Our patients had serious left ventricular dysfunc-tion, however, and, as Liang’s group suggested, the effects of naloxone on myocardial contractility may differ in the left and right ventricles. The naloxone dose used in our clinical studies was substantially higher than that shown to be effective in Liang’s canine model. In fact plasma concentrations were achieved that in vitro have been associated with a non-receptor mediated enhancement of myocardial contractility.30,31

EXERCISE, OPIOID PEPTIDES, AND SYMPTOMS IN HEART FAILURE

Circulating β endorphin concentrations rise acutely after strenuous physical exercise in normal people.32 There is a threshold of exercise intensity for producing this effect and training augments the increase.33 Acute physical exercise in our patients with congestive heart failure also increased the circulating concentration of β endorphin and had a similar effect on ACTH and cortisol. Comparison with the normal volunteer studies cited earlier does not suggest that the exercise induced rise in these circulating hormones is either enhanced or attenuated in patients with stable chronic heart failure. These increases were enhanced, in a dose dependent manner, by the preceding treatment with naloxone. In percentage terms, the largest rise after naloxone was in ACTH, although the reasons for this are not clear. It is not possible to determine whether there is an exercise threshold required to provoke a rise in plasma β endorphin in heart failure as there is in normal people, nor whether the degree of enhance-

ment by naloxone reflects the underlying concentra-tion of activation within the endoge-nous opioid system. In our patients, there was no relation between exercise intensity and β endorphin concentrations before or after exercise, but in 16 patients with dilated cardiomyopathy, Kawashima’s group found that β endorphin concentrations before exercise were inversely correlated with exercise capacity.24

Modulation of opioid receptors may alter the perception of painlessness in patients with heart failure. Davies et al found that naloxone, given intravenously immediately before exercise, increased the sensation of dyspnea at a standard workload and slightly reduced Vo2max. By contrast, dihydro-codeine, an opioid receptor agonist, reduced dyspnea and increased Vo2max. In a finding analogous to that described previously in patients with angina, objective measures of pain sensation correlated with indices of dyspnea.34 The opposite results obtained with the antagonist and agonist in these patients suggested that these effects were receptor mediated. Opioids modify the respiratory response to hypercapnia, but no data on CO2 produc-tion or ventilation were provided. In a second study morphine was given through a nebuliser to patients with heart failure. In this case, the opioid agonist did not reduce either the sensa-tion of dyspnea or maximal ventilation. Despite this, slight but significant improvements in exercise duration and Vo2max were again found.35 In our patients with heart fail-ure, intravenous naloxone had no effect on either symptom perception or exercise capacity. Our patients were similar in age and severity of heart failure to those studied by Kawashima et al32 and Davies et al,34 thus any difference in study population seems unlikely to account for the differing results.

WHAT DO HIGH CIRCULATING CONCENTRATIONS OF OPIOID PEPTIDES MEAN?

Many studies have confirmed that it is diffi-cult to define the level of activity within the sympathetic nervous system and particularly the cardiac adrenergic nerves by monitoring circulating concentrations of adrenaline, the main hormonal component of the system. Similarly it is not known whether there is any correlation between circulating β endorphin concentrations and the level of inhibitory input from presynaptic opioid receptors within areas of the autonomic and central ner-vous systems involved in cardiovascular regu-lation. If there is, then clearly the essentially normal concentrations found in our patients with chronic heart failure would not suggest a significant degree of activation. In patients with cardiogenic shock, who do have high β endorphin concentrations, further studies on the effects of naloxone would be of interest.

IF OPIOID PEPTIDES ARE BAD FOR YOU, WHY DO WE STILL HAVE THEM?

Teleologically, it has been postulated that endorphins are critical to the coping mech-a-nisms and survival of the organism. In a qui-escent state when blood pressure is normal,
opioids are not released and giving an opioid antagonist has, as in our patients, no detectable effect. After a stress such as major haemorrhage, endorphins are released and contribute to analgesia and hypotension. Hypotension may be a highly protective mechanism by reducing the driving pressure in the bleeding vessels and assisting coagulation. Under certain conditions, however, particularly in septic shock, endogenous opioid peptide release may be less helpful and opioid receptor antagonists can produce dramatic improvements in blood pressure.  

In response to other, evolutionary younger stresses, such as acute myocardial infarction, release of opioid peptide may be similarly inappropriate.

KGO was a British Heart Foundation Junior Research Fellow. This study was also supported by the Greater Glasgow Health Board Endowments Fund.

Activation and inhibition of the endogenous opioid system in human heart failure.

K. G. Oldroyd, C. E. Gray, R. Carter, K. Harvey, W. Borland, G. Beastall and S. M. Cobbe

Br Heart J 1995 73: 41-48
doi: 10.1136/hrt.73.1.41

Updated information and services can be found at:
http://heart.bmj.com/content/73/1/41

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/